tbuckley/cabot-search huggingface dataset:
Familial Eosinophilia and Splenomegaly
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sudden Infant Death
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Association Notices -- ARM Motions affecting policy or Association constitution or involving special expenditure
Journal: BMJ (1976)

1483 consistent with the provisions of the White Paper, The Attack on Inflation.A limit of £6 a week was imposed on increases for those whose earnings were below £8500, and the Review Body therefore recommended an increase of £312 a year.The increase should take the form of a separate supplement, which is pen- sionable.
Article on Prostate-Specific Antigen Modulates Genes
Journal: Clinical Cancer Research (2006)

In the article on prostate-specific antigen modulating genes in the March 1, 2006 issue of Clinical Cancer Research, the forward primer sequence in the Materials and Methods section was incorrect. The correct sequence is 5′-ATTCCGCCGGAGAGCTGTGT.Nadiminty N, Lou W, Lee SO, et al. Prostate-specific antigen modulates genes involved in bone remodeling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2. Clin Cancer Res 2006;12:1420–30.
Child Care and Training
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Issue Information
Authors: Daniel Solomon, Richard Bucala, New Haven, Mariana Kaplan, Peter Nigrovic, Boston Co, Karen Costenbader, David Felson, Richard Loeser, Chapel Hill, Paul Sufka, St Paul, Shervin Assassi, Adam Berlinberg, Deborah Feldman, Meenakshi Jolly, Donnamarie Krause, Las Vegas, Uyen-Sa Nguyen, Michelle Ormseth, Nashville Scofield, Oklahoma City, Jane Diamond, Atlanta Ilani, S Lorber, Atlanta Lesley, W Allen, Atlanta Barraza, Emily Wehby, Atlanta Stefanie, L Mckain, Atlanta Swett, Haven Galanis, Marta Alarcón-Riquelme, Heather Allore, Neal Basu, Edward Behrens, Bryce Binstadt, John Carrino, New York, Lisa Christopher-Stine, Baltimore Cope, Nicola Dalbeth, Brian Feldman, Richard Furie, Great Neck, J Kahlenberg, Ann Arbor, Benjamin Leder, Yvonne Lee, Katherine Liao, Anne-Marie Malfait, Stephen Messier, Winston-Salem Janet, E Pope, Christopher Ritchlin, Rochester Robinson, Georg Schett, Sakae Tanaka, Maria Trojanowska, Betty Tsao, Fredrick Wigley, Bing Lu, Abhishek Abhishek, Nottingham Aghayev, Tom Appleton, Joshua Baker, Bonnie Bermas, Dallas Denton, Anisha Dua, John Fitzgerald, Angeles Haroon, Monique Hinchcliff, Hui-Chen Hsu, Vasileios Kyttaris, Rik Lories, Suresh Mahalingam, Dennis Mcgonagle, Aridaman Pandit, Kevin Winthrop, Julie Zikherman, San Francisco, Jamie Collins, David Karp, Kenneth Saag, Douglas White, La Crosse, Deborah Desir, Steven Echard
Journal: Arthritis & Rheumatology (2020)

The fi gure on the cover (from Zuo et al, pages 2130-2135) illustrates the detection of antineutrophil extracellular trap (NET) antibodies from patients with primary antiphospholipid syndrome, by immunofl uorescence microscopy.When NETs were incubated with plasma from patients with high levels of anti-NET IgG, antibodies robustly decorated NET strands.DNA stained blue, neutrophil elastase stained green, and human IgG stained red.This is a merged image.
Mucocutaneous Histoplasmosis
Authors: Rodney S. W. Basler
Journal: JAMA (1974)

PRIMARY inoculation lesions can be caused by fungi that more commonly cause systemic mycotic disease. Such lesions have been shown with<i>Coccidioides immitis</i><sup>1,2</sup>and<i>Blastomyces dermatitidis</i>,<sup>3</sup>among others. Reports also appear in the literature of primary or localized infections of<i>Histoplasma capsulatum</i>occurring in the vagina,<sup>4</sup>eye,<sup>5</sup>and oropharynx,<sup>6,7</sup>as well as on the external cutaneous surface in accidentally infected laboratory personnel.<sup>8,9</sup> A number of criteria have been proposed as critical in establishing the diagnosis of primary inoculation disease.<sup>9,10</sup>Unfortunately, most of the suspected cases of such infection do not conform to all of these criteria; in particular, questions arise in regard to those cases allegedly involving the oropharynx.<sup>11</sup>Most authors suggest that a case of proven histoplasmosis of the oral mucosa, despite an unusual appearance, should be regarded as an indication of systemic disease and approached as such therapeutically. We describe
Regional Notes
Journal: JAMA (1962)

<h3>Work on Doctors' Hospital To Begin Early Next Year</h3> Construction work on Doctors Hospital in Philadelphia will begin early in 1963, Dr. B. H. K. Miller, hospital president, has announced. The five story main building of the present hospital building will be completely refurbished inside and out, Miller said, "becoming a new building in all respects." Construction cost will be $1,200,000. The entrance will be reached by a curved ramp rising to the first floor. The exterior will be gold anodized aluminum grill-work. The ground floor will have a new lobby and reception area, remodeled business and administration offices, a gift shop and snack bar. The first floor's X-ray department will be modernized. On the second floor will be a new operating area. The remainder of the floor will be provided with new patient facilities, including new flooring, lighting, and a nurses' call system. The third floor will have new
Lung Content Analysis of Cases Occupationally Exposed to Chrysotile Asbestos
Authors: R. P. Nolan, A. M. Langer, J. Addison
Journal: Environmental Health Perspectives (1994)

The lung contents of six workers who had been occupationally exposed to chrysotile asbestos were examined.Five were lung cancer cases from Quebec, Canada.The sixth, an American worker who had developed pleural mesothelioma, was particularly interesting, with the lung content strik- ingly distinct from the Canadian cases; chrysotile, the predominant fiber in his lung, was present at a concentration 300 times that of the average total fiber content in the Canadian cases.The fiber length distribution of the chrysotile recovered from the U.S. mesothelioma case was indistin- guishable from that of chrysotile specimens known to produce mesotheliomas in rats.It was also found that the characteristics of the calcium-mag- nesium-iron silicate fibers present in all six cases were not readily comparable to tremolite asbestos specimens known to induce mesotheliomas in animals.
Checkpoint inhibitors in combination with chemotherapy for first-line treatment of advanced nonsquamous non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs).
Authors: Wai Lin Thein, Aung Tun, Elizabeth Guevara, Aymen Elfiky, James Gasperino
Journal: Journal of Clinical Oncology (2019)

125 Background: RCTs have tested the role of adding immunotherapy to standard therapy in patients with advanced non-squamous non-small cell lung cancer (NSCLC) in the first-line setting. We conducted a systematic review and meta-analysis of RCTs to assess the efficacy and toxicity of adding immunotherapy in this patient population. Methods: We systematically conducted a comprehensive literature search using PUBMED, EMBASE and SCOPUS databases through October 1, 2018. RCTs of first-line standard therapy +/- immunotherapy in patients with advanced non-squamous NSCLC were incorporated in the analysis. A generic inverse variance method was used to calculate the estimated pooled Hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS). The mantel-haenszel method was used to calculate the estimated pooled risk ratio (RR) with 95% confidence interval (CI) for pooled overall response rate (ORR), all-grade adverse events (AEs), and high-grade AEs (≥grade 3). Heterogeneity was assessed with Cochrane Q-statistic. Random effects were used due to significant heterogeneity among studies. Results: Three phase 2 &amp; 3 RCTs (Keynote – 021,189 and IMpower – 150) including 1431 patients with advanced non-squamous NSCLC patients were included in the analysis. Keynote 021 &amp; 189 trials did not allow patients with EGFR or ALK mutations, while IMpower 150 trial allowed EGFR or ALK mutations. The study arm used standard regimens in combination with pembrolizumab or atezolizumab while control arm used only standard regimens. The pooled HR for PFS was 0.57 (95% CI: 0.5-0.65; P=0.00001), the pooled HR for OS was 0.61 (95% CI: 0.43-0.87; P=0.006), and the pooled RR for ORR was 1.83 (95 CI: 1.13-2.95; P=0.01). The pooled RRs for all-grade AEs and high-grade AEs were 1 (95% CI: 0.99-1.02; P=0.48) and 1.11 (95% CI: 0.97-1.28; P=0.14), respectively. Conclusions: Pooled data showed significant improvement in PFS, OS &amp; ORR with chemo-immunotherapy compared to the standard treatment regimen for the first-line treatment of advanced non-squamous NSCLC. There was no increase in the risk of all-grade and high-grade AEs.
Correlation between miRNA and gene expression profiles and response to neoadjuvant chemotherapy in patients with locally advanced and inflammatory breast cancer.
Authors: G. Somlo, S. M. Li, X. Wu, S. Lau, P. H. Frankel, L. Kruper, H. Gao, G. Sun, J. H. Yim, A. Hurria, J. E. Mortimer, F. De Snoo, I. B. Paz, J. Rossi, E. Wang, P. Roepman, Y. Yen, L. van't Veer, R. A. Bender
Journal: Journal of Clinical Oncology (2011)

548 Background: Gene expression profiling may predict for pathologic complete response (pCR) after neoadjuvant therapy (NT). Identification of both miRNA and gene expression may yield novel targets and improved NT. Methods: Patients (pts) with HER2− locally advanced/inflammatory breast cancer (BC) were randomized to receive docetaxel, doxorubicin, cyclophosphamide (TAC, arm A), or A and C given every 2 weeks × 4, followed by carboplatin and nab-paclitaxel (arm B). Pts with HER2+ BC received NT similar to arm B, with trastuzumab (arm C). Core biopsies were snap-frozen prior to NT, and RNA was extracted for gene array analysis (MammaPrint, BluePrint: basal, luminal, and HER2 profiling, and Agilent 44K microarray), and for deep sequence miRNA analysis with the Solexa/Illumina platform. Pathological assessment included grade, ER, HER2 expression, and evidence of residual BC vs.pCR. Unsupervised hierarchical clustering analysis and Fisher’s exact tests were utilized to assess for correlation between miRNA and gene expression, and pathologic assessment. Significant analysis of microarrays (SAM) was used to identify miRNAs differentially expressed and predictive for response (pCR vs. other) to NT. Results: miRNA expression was measured in 72 of 119 enrolled pts; 487 of the 882 miRNAs sequenced, were expressed with raw counts of > 10 in at least 3 pts. miRNA expression patterns revealed three distinct pt clusters, which were significantly associated with the 3 BluePrint subtypes and ER status (Fisher’s exact test, P-values < 1e-5), and moderately associated with HER2 status and MammaPrint classes at borderline significance (P-value: 0.08 and 0.05). SAM identified 6 up and 9 down-regulated miRNAs associated with pCR in HER2− patients (N=43, 4 pCRs) with ≥2 fold changes at false discovery rate (FDR) < 10%. No significant signals of miRNA expression associated with pCR were found in HER2+ pts (N=28; 13 pCRs) at the same FDR level. Conclusions: Combined assessment of miRNA and gene expression patterns is feasible, and pending validation, may yield information leading to individualized and improved NT.
Real-world outcomes in second-line treatment of metastatic castration-resistant prostate cancer (mCRPC): The Prostate Cancer Registry.
Authors: Simon Chowdhury, Alison J. Birtle, Anders Bjartell, Luis Costa, Susan Feyerabend, Luca Galli, Ewa Kalinka-Warzocha, Gero Kramer, Nicolaas Lumen, Pablo Maroto, Vsevolod B Matveev, Thomas Paiss, Salvatore Pisconti, Dominique Spaeth, Francisco Gomez Veiga, Laurent Antoni, Edwin Klumper, Robert Wapenaar, Erik van den Berg, Emma Lee
Journal: Journal of Clinical Oncology (2017)

5028 Background: The Prostate Cancer Registry is a prospective, international observational study that began in June 2013 and will assess the characteristics and management of &gt; 3000 mCRPC patients (pts) in routine clinical practice for ≤ 3 years. Methods: Data were collected from men with mCRPC irrespective of treatment (tx). This interim analysis reports baseline characteristics, txs and outcomes in pts with ≥ 12-month follow-up receiving second-line mCRPC tx following docetaxel as the only prior mCRPC tx. Results: The most commonly initiated second-line mCPRC txs (n ≥ 50) were abiraterone acetate + prednisone (AAP, n = 177), enzalutamide (ENZ, n = 94), or cabazitaxel (CAB, n = 70). Characteristics and outcomes are shown in the table below. TTP was not significantly different for AAP vs ENZ, AAP vs CAB or ENZ vs CAB (propensity score adjusted p = 0.5954, p = 0.5888 and p= 0.4808, respectively). Conclusions: In this real-world study, clinical outcomes reveal that, in pts receiving second-line mCRPC tx after docetaxel, TTP was similar across tx groups; QoL improved most in AAP and ENZ groups and no deterioration was observed most in AAP and CAB groups. Clinical trial information: NCT02236637. [Table: see text]
Harefuah, Tel-Aviv
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Quinin OR ARSENIC IN CHOREA.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE UTILITY OF CLOPIDOGREL RELOADING FOR PATIENTS PRESENTING WITH ACUTE CORONARY SYNDROME WHO ARE ON CHRONIC CLOPIDOGREL THERAPY AND UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
Authors: Asmir I. Syed, Michael Mahmoudi, Itsik Ben-Dor, Michael A. Gaglia, Sara D. Collins, Gabriel Maluenda, Manuel Gonzalez, Kohei Wakabayashi, Gabriel Sardi, Rafael Romaguera, Anna Laynez, Rebecca Torguson, Zhenyi Xue, Nelson Bernardo, Joseph Lindsay, Kenneth M. Kent, Lowell F. Satler, William O. Suddath, Augusto D. Pichard, Ron Waksman
Journal: Journal of the American College of Cardiology (2011)
FDA Approves Selpercatinib; Pralsetinib May Soon Follow
Journal: Cancer Discovery (2020)

Abstract The FDA has greenlighted selpercatinib, the first targeted therapy for RET-altered non–small cell lung cancer (NSCLC) and certain types of thyroid cancer. Another RET inhibitor, pralsetinib, has been submitted for approval to treat NSCLC. Both drugs have shown effectiveness in treating brain metastases.
A CASE OF MULTIPLE CRANIAL NERVE PALSY DUE TO EXTRACRANIAL DISEASE
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE SUPPLY OF PHYSICIANS
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal